Immunologic effects of intranasal corticosteroids

Area of Science:

• Allergy and Immunology
• Pharmacology
• Otolaryngology

Background:

• Intranasal corticosteroids are the primary treatment for moderate to severe allergic rhinitis, nonallergic rhinitis, and nasal polyposis.
• They possess a wide safety margin, with no evidence of nasal mucosal atrophy or hypothalamic-pituitary-adrenal (HPA) suppression with long-term, recommended use.

Purpose of the Study:

• To evaluate the efficacy and safety of intranasally administered corticosteroids.
• To understand their immunologic mechanisms in reducing rhinitic symptoms.

Main Methods:

• Review of clinical data and immunologic studies on intranasal corticosteroid use.
• Analysis of effects on early and late phase allergen challenge responses.
• Assessment of changes in inflammatory cells and mediators in nasal lavage and submucosa.

Main Results:

• Intranasal corticosteroids effectively inhibit early and late allergic responses and reduce inflammatory cells like eosinophils and basophils.
• They decrease activated lymphocytes (CD4+ CD25+) and bioactive mediators, including interleukin-4 (IL-4) producing cells.
• Despite potency differences, available preparations show similar therapeutic effectiveness.

Conclusions:

• Intranasal corticosteroids are safe and effective for various nasal inflammatory conditions, providing significant symptom relief.
• Their immunomodulatory actions contribute to their therapeutic benefits.
• They are a crucial component of rhinitis management but do not replace environmental control or allergen immunotherapy.